[go: up one dir, main page]
More Web Proxy on the site http://driver.im/ Skip to main content

Advertisement

Springer Nature Link
Log in

NADPH oxidase inhibitors: a decade of discovery from Nox2ds to HTS

  • Multi-author review
  • Published:
Cellular and Molecular Life Sciences Aims and scope Submit manuscript

Abstract

NADPH oxidases (Nox) are established as major sources of reactive oxygen species (ROS). Over the past two decades, Nox-derived ROS have emerged as pivotal in the development of myriad diseases involving oxidative stress. In contrast, Nox are also involved in signaling mechanisms necessary for normal cell function. The study of these enzymes in physiological and pathophysiological conditions is made considerably more complex by the discovery of 7 isoforms: Nox1 through 5 as well as Duox1 and 2, each with its own specific cytosolic components, regulatory control mechanisms, subcellular localization and/or tissue distribution. A clear understanding of the role individual isoforms play in a given system is hindered by the lack of isoform-specific inhibitors. In animal models, knockdown or knockout methodologies are providing definitive answers to perplexing questions of the complex interplay of multiple Nox isoforms in cell and tissue signaling. However, the complex structures and interactions of these heteromeric isozymes predict pleiotropic actions of the Nox subunits and thus suppression of these proteins is almost certain to have untoward effects. Thus, as both therapies and pharmacological tools, molecule-based inhibitors continue to prove extremely useful and rational in design. Unfortunately, many of the available inhibitors have proven non-specific, falling into the category of scavengers or inhibitors of more than one source of ROS. Here, we will review some of the efforts that have been undertaken to develop specific inhibitors of NADPH oxidase over the past decade, from the peptidic inhibitor Nox2ds-tat to more recent small molecule inhibitors that have emerged from high-throughput screening campaigns.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
£29.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (United Kingdom)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bedard K, Krause KH (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87:245–313

    Article  PubMed  CAS  Google Scholar 

  2. Lambeth JD (2007) Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med 43:332–347

    Article  PubMed  CAS  Google Scholar 

  3. Lambeth JD, Krause KH, Clark RA (2008) NOX enzymes as novel targets for drug development. Semin Immunopathol 30:339–363

    Article  PubMed  CAS  Google Scholar 

  4. Csanyi G, Taylor WR, Pagano PJ (2009) NOX and inflammation in the vascular adventitia. Free Radic Biol Med 47:1254–1266

    Article  PubMed  CAS  Google Scholar 

  5. Brown DI, Griendling KK (2009) Nox proteins in signal transduction. Free Radic Biol Med 47:1239–1253

    Article  PubMed  CAS  Google Scholar 

  6. Sumimoto H (2008) Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J 275:3249–3277

    Article  PubMed  CAS  Google Scholar 

  7. El-Benna J, Dang PM, Perianin A (2010) Peptide-based inhibitors of the phagocyte NADPH oxidase. Biochem Pharmacol 80:778–785

    Article  PubMed  CAS  Google Scholar 

  8. Liu J, Yang F, Yang XP, Jankowski M, Pagano PJ (2003) NAD(P)H oxidase mediates angiotensin II-induced vascular macrophage infiltration and medial hypertrophy. Arterioscler Thromb Vasc Biol 23:776–782

    Article  PubMed  CAS  Google Scholar 

  9. Rey FE, Cifuentes ME, Kiarash A, Quinn MT, Pagano PJ (2001) Novel competitive inhibitor of NAD(P)H oxidase assembly attenuates vascular O(2)(−) and systolic blood pressure in mice. Circ Res 89:408–414

    Article  PubMed  CAS  Google Scholar 

  10. Touyz RM, Chen X, Tabet F, Yao G, He G, Quinn MT, Pagano PJ, Schiffrin EL (2002) Expression of a functionally active gp91phox-containing neutrophil-type NAD(P)H oxidase in smooth muscle cells from human resistance arteries. Regulation by angiotensin II. Circ Res 90:1205–1213

    Article  PubMed  CAS  Google Scholar 

  11. Jacobson GM, Dourron HM, Liu J, Carretero OA, Reddy DJ, Andrzejewski T, Pagano PJ (2003) Novel NAD(P)H oxidase inhibitor suppresses angioplasty-induced superoxide and neointimal hyperplasia of rat carotid artery. Circ Res 92:637–643

    Article  PubMed  CAS  Google Scholar 

  12. Fawell S, Seery J, Daikh Y, Moore C, Chen LL, Pepinsky B, Barsoum J (1994) Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 91:664–668

    Article  PubMed  CAS  Google Scholar 

  13. DeLeo FR, Yu L, Burritt JB, Loetterle LR, Bond CW, Jesaitis AJ, Quinn MT (1995) Mapping sites of interaction of p47-phox and flavocytochrome b with random-sequence peptide phage display libraries. Proc Natl Acad Sci USA 92:7110–7114

    Article  PubMed  CAS  Google Scholar 

  14. Al-Shabrawey M, Bartoli M, El-Remessy AB, Platt DH, Matragoon S, Behzadian MA, Caldwell RW, Caldwell RB (2005) Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am J Pathol 167:599–607

    Article  PubMed  CAS  Google Scholar 

  15. Lopes NHM, Vasudevan SS, Gregg D, Selvakumar B, Pagano PJ, Kovacic H, Goldschmidt-Clermont PJ (2002) Rac-dependent monocyte chemoattractant protein-1 production is induced by nutrient deprivation. Circ Res 91:798–805

    Article  PubMed  CAS  Google Scholar 

  16. Furst R, Brueckl C, Kuebler WM, Zahler S, Krotz F, Gorlach A, Vollmar AM, Kiemer AK (2005) Atrial natriuretic peptide induces mitogen-activated protein kinase phosphatase-1 in human endothelial cells via Rac1 and NAD(P)H oxidase/Nox2-activation. Circ Res 96:43–53

    Article  PubMed  Google Scholar 

  17. Harfouche R, Malak NA, Brandes RP, Karsan A, Irani K, Hussain SN (2005) Roles of reactive oxygen species in angiopoietin-1/tie-2 receptor signaling. FASEB J 19:1728–1730

    PubMed  CAS  Google Scholar 

  18. Walch L, Massade L, Dufilho M, Brunet A, Rendu F (2006) Pro-atherogenic effect of interleukin-4 in endothelial cells: modulation of oxidative stress, nitric oxide and monocyte chemoattractant protein-1 expression. Atherosclerosis 187:285–291

    Article  PubMed  CAS  Google Scholar 

  19. Duerrschmidt N, Stielow C, Muller G, Pagano PJ, Morawietz H (2006) NO-mediated regulation of NAD(P)H oxidase by laminar shear stress in human endothelial cells. J Physiol 576:557–567

    Article  PubMed  CAS  Google Scholar 

  20. Krotz F, Keller M, Derflinger S, Schmid H, Gloe T, Bassermann F, Duyster J, Cohen CD, Schuhmann C, Klauss V, Pohl U, Stempfle HU, Sohn HY (2007) Mycophenolate acid inhibits endothelial NAD(P)H oxidase activity and superoxide formation by a Rac1-dependent mechanism. Hypertension 49:201–208

    Article  PubMed  Google Scholar 

  21. Krotz F, Sohn HY, Gloe T, Zahler S, Riexinger T, Schiele TM, Becker BF, Theisen K, Klauss V, Pohl U (2002) NAD(P)H oxidase-dependent platelet superoxide anion release increases platelet recruitment. Blood 100:917–924

    Article  PubMed  CAS  Google Scholar 

  22. Jung O, Schreiber JG, Geiger H, Pedrazzini T, Busse R, Brandes RP (2004) gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation 109:1795–1801

    Article  PubMed  CAS  Google Scholar 

  23. Liu J, Ormsby A, Oja-Tebbe N, Pagano PJ (2004) Gene transfer of NAD(P)H oxidase inhibitor to the vascular adventitia attenuates medial smooth muscle hypertrophy. Circ Res 95:587–594

    Article  PubMed  CAS  Google Scholar 

  24. Dourron HM, Jacobson GM, Park JL, Liu J, Reddy DJ, Scheel ML, Pagano PJ (2005) Perivascular gene transfer of NADPH oxidase inhibitor suppresses angioplasty-induced neointimal proliferation of rat carotid artery. Am J Physiol Heart Circ Physiol 288:H946–H953

    Article  PubMed  CAS  Google Scholar 

  25. Weaver M, Liu J, Pimentel D, Reddy DJ, Harding P, Peterson EL, Pagano PJ (2006) Adventitial delivery of dominant-negative p67phox attenuates neointimal hyperplasia of the rat carotid artery. Am J Physiol Heart Circ Physiol 290:H1933–H1941

    Article  PubMed  CAS  Google Scholar 

  26. Banfi B, Clark RA, Steger K, Krause KH (2003) Two novel proteins activate superoxide generation by the NADPH oxidase NOX1. J Biol Chem 278:3510–3513

    Article  PubMed  CAS  Google Scholar 

  27. Jackson HM, Kawahara T, Nisimoto Y, Smith SM, Lambeth JD (2010) Nox4 B-loop creates an interface between the transmembrane and dehydrogenase domains. J Biol Chem 285:10281–10290

    Article  PubMed  CAS  Google Scholar 

  28. Csanyi G, Cifuentes-Pagano E, Al Ghouleh I, Ranayhossaini DJ, Egana L, Lopes LR, Jackson HM, Kelley EE, Pagano PJ (2011) Nox2 B-loop peptide, Nox2ds, specifically inhibits the NADPH oxidase Nox2. Free Radic Biol Med 51(6):1116–1125

    Article  PubMed  CAS  Google Scholar 

  29. Rotrosen D, Kleinberg ME, Nunoi H, Leto T, Gallin JI, Malech HL (1990) Evidence for a functional cytoplasmic domain of phagocyte oxidase cytochrome b558. J Biol Chem 265:8745–8750

    PubMed  CAS  Google Scholar 

  30. Nakanishi A, Imajoh-Ohmi S, Fujinawa T, Kikuchi H, Kanegasaki S (1992) Direct evidence for interaction between COOH-terminal regions of cytochrome b558 subunits and cytosolic 47-kDa protein during activation of an O(2−)-generating system in neutrophils. J Biol Chem 267:19072–19074

    PubMed  CAS  Google Scholar 

  31. Leusen JH, de Boer M, Bolscher BG, Hilarius PM, Weening RS, Ochs HD, Roos D, Verhoeven AJ (1994) A point mutation in gp91-phox of cytochrome b558 of the human NADPH oxidase leading to defective translocation of the cytosolic proteins p47-phox and p67-phox. J Clin Invest 93:2120–2126

    Article  PubMed  CAS  Google Scholar 

  32. Park MY, Imajoh-Ohmi S, Nunoi H, Kanegasaki S (1997) Synthetic peptides corresponding to various hydrophilic regions of the large subunit of cytochrome b558 inhibit superoxide generation in a cell-free system from neutrophils. Biochem Biophys Res Commun 234:531–536

    Article  PubMed  CAS  Google Scholar 

  33. Yu L, Cross AR, Zhen L, Dinauer MC (1999) Functional analysis of NADPH oxidase in granulocytic cells expressing a delta488–497 gp91(phox) deletion mutant. Blood 94:2497–2504

    PubMed  CAS  Google Scholar 

  34. Dahan I, Issaeva I, Gorzalczany Y, Sigal N, Hirshberg M, Pick E (2002) Mapping of functional domains in the p22(phox) subunit of flavocytochrome b(559) participating in the assembly of the NADPH oxidase complex by “peptide walking”. J Biol Chem 277:8421–8432

    Article  PubMed  CAS  Google Scholar 

  35. Park MY, Imajoh-Ohmi S, Nunoi H, Kanegasaki S (1994) Peptides corresponding to the region adjacent to His-94 in the small subunit of cytochrome b558 inhibit superoxide generation in a cell-free system from human neutrophils. Biochem Biophys Res Commun 204:924–929

    Article  PubMed  CAS  Google Scholar 

  36. von Lohneysen K, Noack D, Jesaitis AJ, Dinauer MC, Knaus UG (2008) Mutational analysis reveals distinct features of the Nox4-p22 phox complex. J Biol Chem 283:35273–35282

    Article  Google Scholar 

  37. Nauseef WM, McCormick S, Renee J, Leidal KG, Clark RA (1993) Functional domain in an arginine-rich carboxyl-terminal region of p47phox. J Biol Chem 268:23646–23651

    PubMed  CAS  Google Scholar 

  38. Labadia ME, Zu YL, Huang CK (1996) A synthetic peptide containing a predominant protein kinase C site within p47phox inhibits the NADPH oxidase in intact neutrophils. J Leukoc Biol 59:116–124

    PubMed  CAS  Google Scholar 

  39. DeLeo FR, Nauseef WM, Jesaitis AJ, Burritt JB, Clark RA, Quinn MT (1995) A domain of p47phox that interacts with human neutrophil flavocytochrome b558. J Biol Chem 270:26246–26251

    Article  PubMed  CAS  Google Scholar 

  40. Lassegue B, Clempus RE (2003) Vascular NAD(P)H oxidases: specific features, expression, and regulation. Am J Physiol Regul Integr Comp Physiol 285:R277–R297

    PubMed  CAS  Google Scholar 

  41. Martyn KD, Frederick LM, von Loehneysen K, Dinauer MC, Knaus UG (2006) Functional analysis of Nox4 reveals unique characteristics compared to other NADPH oxidases. Cell Signal 18:69–82

    Article  PubMed  CAS  Google Scholar 

  42. D’Addio SM, Prud’homme RK (2011) Controlling drug nanoparticle formation by rapid precipitation. Adv Drug Deliv Rev 63(6):417–426

    Google Scholar 

  43. De Koker S, De Cock LJ, Rivera-Gil P, Parak WJ, Auzely Velty R, Vervaet C, Remon JP, Grooten J, De Geest BG (2011) Polymeric multilayer capsules delivering biotherapeutics. Adv Drug Deliv Rev 63(9):748–761

    Google Scholar 

  44. Brandes RP, Schroder K (2008) Composition and Functions of Vascular Nicotinamide Adenine Dinucleotide Phosphate Oxidases. Trends Cardiovasc Med 18:15–19

    Article  PubMed  CAS  Google Scholar 

  45. Aldieri E, Riganti C, Polimeni M, Gazzano E, Lussiana C, Campia I, Ghigo D (2008) Classical inhibitors of NOX NAD(P)H oxidases are not specific. Curr Drug Metab 9:686–696

    Article  PubMed  CAS  Google Scholar 

  46. Diatchuk V, Lotan O, Koshkin V, Wikstroem P, Pick E (1997) Inhibition of NADPH oxidase activation by 4-(2-aminoethyl)-benzenesulfonyl fluoride and related compounds. J Biol Chem 272:13292–13301

    Article  PubMed  CAS  Google Scholar 

  47. Cayatte AJ, Rupin A, Oliver-Krasinski J, Maitland K, Sansilvestri-Morel P, Boussard MF, Wierzbicki M, Verbeuren TJ, Cohen RA (2001) S17834, a new inhibitor of cell adhesion and atherosclerosis that targets nadph oxidase. Arterioscler Thromb Vasc Biol 21:1577–1584

    Article  PubMed  CAS  Google Scholar 

  48. Jaquet V, Scapozza L, Clark R, Krause KH, Lambeth JD (2009) Small molecule NOX inhibitors: ROS-generating NADPH oxidases as therapeutic targets. Antioxid Redox Signal 11(10):2535–2552

    Google Scholar 

  49. Williams HC, Griendling KK (2007) NADPH oxidase inhibitors: new antihypertensive agents? J Cardiovasc Pharmacol 50:9–16

    Article  PubMed  CAS  Google Scholar 

  50. Selemidis S, Sobey CG, Wingler K, Schmidt HH, Drummond GR (2008) NADPH oxidases in the vasculature: molecular features, roles in disease and pharmacological inhibition. Pharmacol Ther 120:254–291

    Article  PubMed  CAS  Google Scholar 

  51. Cifuentes ME, Pagano PJ (2006) Targeting reactive oxygen species in hypertension. Curr Opin Nephrol Hypertens 15:179–186

    Article  PubMed  CAS  Google Scholar 

  52. ten Freyhaus H, Huntgeburth M, Wingler K, Schnitker J, Baumer AT, Vantler M, Bekhite MM, Wartenberg M, Sauer H, Rosenkranz S (2006) Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc Res 71:331–341

    Article  PubMed  Google Scholar 

  53. Lange S, Heger J, Euler G, Wartenberg M, Piper HM, Sauer H (2009) Platelet-derived growth factor BB stimulates vasculogenesis of embryonic stem cell-derived endothelial cells by calcium-mediated generation of reactive oxygen species. Cardiovasc Res 81:159–168

    Article  PubMed  CAS  Google Scholar 

  54. Stielow C, Catar RA, Muller G, Wingler K, Scheurer P, Schmidt HH, Morawietz H (2006) Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells. Biochem Biophys Res Commun 344:200–205

    Article  PubMed  CAS  Google Scholar 

  55. Wind S, Beuerlein K, Armitage ME, Taye A, Kumar AH, Janowitz D, Neff C, Shah AM, Wingler K, Schmidt HH (2010) Oxidative stress and endothelial dysfunction in aortas of aged spontaneously hypertensive rats by NOX1/2 is reversed by NADPH oxidase inhibition. Hypertension 56:490–497

    Article  PubMed  CAS  Google Scholar 

  56. Tsai MH, Jiang MJ (2010) Reactive oxygen species are involved in regulating alpha1-adrenoceptor-activated vascular smooth muscle contraction. J Biomed Sci 17:67

    Article  PubMed  Google Scholar 

  57. Kleinschnitz C, Grund H, Wingler K, Armitage ME, Jones E, Mittal M, Barit D, Schwarz T, Geis C, Kraft P, Barthel K, Schuhmann MK, Herrmann AM, Meuth SG, Stoll G, Meurer S, Schrewe A, Becker L, Gailus-Durner V, Fuchs H, Klopstock T, de Angelis MH, Jandeleit-Dahm K, Shah AM, Weissmann N, Schmidt HH (2010) Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS Biol 8(9). pii:e1000479

  58. Milosevic N, Bekhite MM, Sharifpanah F, Ruhe C, Wartenberg M, Sauer H (2010) Redox stimulation of cardiomyogenesis versus inhibition of vasculogenesis upon treatment of mouse embryonic stem cells with thalidomide. Antioxid Redox Signal 13:1813–1827

    Article  PubMed  CAS  Google Scholar 

  59. Sancho P, Fabregat I (2011) The NADPH oxidase inhibitor VAS2870 impairs cell growth and enhances TGF-beta-induced apoptosis of liver tumor cells. Biochem Pharmacol 81:917–924

    Article  PubMed  CAS  Google Scholar 

  60. Wind S, Beuerlein K, Eucker T, Muller H, Scheurer P, Armitage ME, Ho H, Schmidt HH, Wingler K (2010) Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br J Pharmacol 161:885–898

    Article  PubMed  CAS  Google Scholar 

  61. Perry BN, Govindarajan B, Bhandarkar SS, Knaus UG, Valo M, Sturk C, Carrillo CO, Sohn A, Cerimele F, Dumont D, Losken A, Williams J, Brown LF, Tan X, Ioffe E, Yancopoulos GD, Arbiser JL (2006) Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol 126:2316–2322

    Article  PubMed  CAS  Google Scholar 

  62. Berrios RL, Arbiser JL (2011) Novel antiangiogenic agents in dermatology. Arch Biochem Biophys 508:222–226

    Article  PubMed  CAS  Google Scholar 

  63. Bhandarkar SS, Jaconi M, Fried LE, Bonner MY, Lefkove B, Govindarajan B, Perry BN, Parhar R, Mackelfresh J, Sohn A, Stouffs M, Knaus U, Yancopoulos G, Reiss Y, Benest AV, Augustin HG, Arbiser JL (2009) Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. J Clin Invest 119:2359–2365

    PubMed  CAS  Google Scholar 

  64. Laleu B, Gaggini F, Orchard M, Fioraso-Cartier L, Cagnon L, Houngninou-Molango S, Gradia A, Duboux G, Merlot C, Heitz F, Szyndralewiez C, Page P (2010) First in class, potent, and orally bioavailable NADPH oxidase isoform 4 (Nox4) inhibitors for the treatment of idiopathic pulmonary fibrosis. J Med Chem 53:7715–7730

    Article  PubMed  CAS  Google Scholar 

  65. Sedeek M, Callera G, Montezano A, Gutsol A, Heitz F, Szyndralewiez C, Page P, Kennedy CR, Burns KD, Touyz RM, Hebert RL (2010) Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol 299:F1348–F1358

    Article  PubMed  CAS  Google Scholar 

  66. Garrido-Urbani S, Jemelin S, Deffert C, Carnesecchi S, Basset O, Szyndralewiez C, Heitz F, Page P, Montet X, Michalik L, Arbiser J, Ruegg C, Krause KH, Imhof B (2011) Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARalpha mediated mechanism. PLoS One 6:e14665

    Article  PubMed  CAS  Google Scholar 

  67. Lassegue B, Sorescu D, Szocs K, Yin Q, Akers M, Zhang Y, Grant SL, Lambeth JD, Griendling KK (2001) Novel gp91(phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res 88:888–894

    Article  PubMed  CAS  Google Scholar 

  68. Ray R, Murdoch CE, Wang M, Santos CX, Zhang M, Alom-Ruiz S, Anilkumar N, Ouattara A, Cave AC, Walker SJ, Grieve DJ, Charles RL, Eaton P, Brewer AC, Shah AM (2011) Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol 31:1368–1376

    Article  PubMed  CAS  Google Scholar 

  69. Zhang M, Brewer AC, Schroder K, Santos CX, Grieve DJ, Wang M, Anilkumar N, Yu B, Dong X, Walker SJ, Brandes RP, Shah AM (2010) NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci USA 107:18121–18126

    Article  PubMed  CAS  Google Scholar 

  70. Gianni D, Taulet N, Zhang H, DerMardirossian C, Kister J, Martinez L, Roush WR, Brown SJ, Bokoch GM, Rosen H (2010) A novel and specific NADPH oxidase-1 (Nox1) small-molecule inhibitor blocks the formation of functional invadopodia in human colon cancer cells. ACS Chem Biol 5:981–993

    Article  PubMed  CAS  Google Scholar 

  71. Brinker AM, Ma J, Lipsky PE, Raskin I (2007) Medicinal chemistry and pharmacology of genus Tripterygium (Celastraceae). Phytochemistry 68:732–766

    Article  PubMed  CAS  Google Scholar 

  72. Kannaiyan R, Shanmugam MK, Sethi G (2011) Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett 303:9–20

    Article  PubMed  CAS  Google Scholar 

  73. Wu F, Han M, Wilson JX (2009) Tripterine prevents endothelial barrier dysfunction by inhibiting endogenous peroxynitrite formation. Br J Pharmacol 157:1014–1023

    Article  PubMed  CAS  Google Scholar 

  74. Jaquet V, Marcoux J, Forest E, Leidal KG, McCormick S, Westermaier Y, Perozzo R, Plastre O, Fioraso-Cartier L, Diebold B, Scapozza L, Nauseef WM, Fieschi F, Krause KH, Bedard K (2011) NOX NADPH oxidase isoforms are inhibited by celastrol with a dual mode of action. Br J Pharmacol 164(2b):507–520

    Google Scholar 

  75. Zhang T, Hamza A, Cao X, Wang B, Yu S, Zhan CG, Sun D (2008) A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 7:162–170

    Article  PubMed  CAS  Google Scholar 

  76. Allison AC, Cacabelos R, Lombardi VR, Alvarez XA, Vigo C (2001) Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatr 25:1341–1357

    Article  CAS  Google Scholar 

  77. Kim Y, Kim K, Lee H, Han S, Lee YS, Choe J, Kim YM, Hahn JH, Ro JY, Jeoung D (2009) Celastrol binds to ERK and inhibits FcepsilonRI signaling to exert an anti-allergic effect. Eur J Pharmacol 612:131–142

    Article  PubMed  CAS  Google Scholar 

  78. Borbely G, Szabadkai I, Horvath Z, Marko P, Varga Z, Breza N, Baska F, Vantus T, Huszar M, Geiszt M, Hunyady L, Buday L, Orfi L, Keri G (2010) Small-molecule inhibitors of NADPH oxidase 4. J Med Chem 53:6758–6762

    Article  PubMed  CAS  Google Scholar 

  79. Vendrov AE, Madamanchi NR, Niu XL, Molnar KC, Runge M, Szyndralewiez C, et al. (2010) NADPH oxidases regulate CD44 and hyaluronic acid expression in thrombin-treated vascular smooth muscle cells and in atherosclerosis. J Biol Chem 285:26545–26557

    Google Scholar 

  80. Briones MA, Tabet F, Callera GE, Montezano AC, Yogi A, He Y, Quinn MT, Salaices M, Touyz RM (2011) Differential regulation of Nox1, Nox2 and Nox4 in vascular smooth muscle cells from WKY and SHR. J Am Soc Hypertension 5:137–153

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacology and Chemical Biology, Vascular Medicine Institute, University of Pittsburgh, E-1247 Basic Science Tower, 200 Lothrop St., Pittsburgh, PA, 15261, USA

    Eugenia Cifuentes-Pagano, Gabor Csanyi & Patrick J. Pagano

Authors
  1. Eugenia Cifuentes-Pagano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gabor Csanyi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patrick J. Pagano
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrick J. Pagano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cifuentes-Pagano, E., Csanyi, G. & Pagano, P.J. NADPH oxidase inhibitors: a decade of discovery from Nox2ds to HTS. Cell. Mol. Life Sci. 69, 2315–2325 (2012). https://doi.org/10.1007/s00018-012-1009-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00018-012-1009-2

Keywords

Search

Navigation